Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

Sara Van de Veire; Ingeborg Stalmans; Femke Heindryckx; Hajimu Oura; Annemilaï Tijeras-Raballand; Thomas Schmidt; Sonja Loges; Imke Albrecht; Bart Jonckx; Stefan Vinckier; Christophe Van Steenkiste; Sònia Tugues; Charlotte Rolny; Maria De Mol; Daniela Dettori; Patricia Hainaud; Lieve Coenegrachts; Jean Olivier Contreres; Tine Van Bergen; Henar Cuervo; Wei Hong Xiao; Carole Le Henaff; Ian Buysschaert; Behzad Kharabi Masouleh; Anja Geerts; Tibor Schomber; Philippe Bonnin; Vincent Lambert; Jurgen Haustraete; Serena Zacchigna; Jean Marie Rakic; Wladimiro Jiménez; Agnes Noël; Mauro Giacca; Isabelle Colle; Jean Michel Foidart; Gerard Tobelem; Manuel Morales-Ruiz; José Vilar; Patrick Maxwell; Stanley A. Vinores; Geert Carmeliet; Mieke Dewerchin; Lena Claesson-Welsh; Evelyne Dupuy; Hans Van Vlierberghe; Gerhard Christofori; Massimiliano Mazzone; Michael Detmar; Désiré Collen

doi:10.1016/j.cell.2010.02.039

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

Sara Van de Veire, Ingeborg Stalmans, Femke Heindryckx, Hajimu Oura, Annemilaï Tijeras-Raballand, Thomas Schmidt, Sonja Loges, Imke Albrecht, Bart Jonckx, Stefan Vinckier, Christophe Van Steenkiste, Sònia Tugues, Charlotte Rolny, Maria De Mol, Daniela Dettori, Patricia Hainaud, Lieve Coenegrachts, Jean Olivier Contreres, Tine Van Bergen, Henar CuervoWei Hong Xiao, Carole Le Henaff, Ian Buysschaert, Behzad Kharabi Masouleh, Anja Geerts, Tibor Schomber, Philippe Bonnin, Vincent Lambert, Jurgen Haustraete, Serena Zacchigna, Jean Marie Rakic, Wladimiro Jiménez, Agnes Noël, Mauro Giacca, Isabelle Colle, Jean Michel Foidart, Gerard Tobelem, Manuel Morales-Ruiz, José Vilar, Patrick Maxwell, Stanley A. Vinores, Geert Carmeliet, Mieke Dewerchin, Lena Claesson-Welsh, Evelyne Dupuy, Hans Van Vlierberghe, Gerhard Christofori, Massimiliano Mazzone, Michael Detmar, Désiré Collen

Cardiovascular Medicine & Sciences

Research output: Contribution to journal › Article › peer-review

239 Citations (Scopus)

Abstract

Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

Original language	English
Pages (from-to)	178-190
Number of pages	13
Journal	Cell
Volume	141
Issue number	1
DOIs	https://doi.org/10.1016/j.cell.2010.02.039
Publication status	Published - 1 Jan 2010

Keywords

Cellcylce
Cellimunno
Humdisease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2010.02.039

Cite this

Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., Van Steenkiste, C., Tugues, S., Rolny, C., De Mol, M., Dettori, D., Hainaud, P., Coenegrachts, L., Contreres, J. O., Van Bergen, T., ... Collen, D. (2010). Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. Cell, 141(1), 178-190. https://doi.org/10.1016/j.cell.2010.02.039

@article{06e395dad3964e39b01bc4ee4aa29609,

title = "Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease",

abstract = "Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.",

keywords = "Cellcylce, Cellimunno, Humdisease",

author = "{Van de Veire}, Sara and Ingeborg Stalmans and Femke Heindryckx and Hajimu Oura and Annemila{\"i} Tijeras-Raballand and Thomas Schmidt and Sonja Loges and Imke Albrecht and Bart Jonckx and Stefan Vinckier and {Van Steenkiste}, Christophe and S{\`o}nia Tugues and Charlotte Rolny and {De Mol}, Maria and Daniela Dettori and Patricia Hainaud and Lieve Coenegrachts and Contreres, {Jean Olivier} and {Van Bergen}, Tine and Henar Cuervo and Xiao, {Wei Hong} and {Le Henaff}, Carole and Ian Buysschaert and Masouleh, {Behzad Kharabi} and Anja Geerts and Tibor Schomber and Philippe Bonnin and Vincent Lambert and Jurgen Haustraete and Serena Zacchigna and Rakic, {Jean Marie} and Wladimiro Jim{\'e}nez and Agnes No{\"e}l and Mauro Giacca and Isabelle Colle and Foidart, {Jean Michel} and Gerard Tobelem and Manuel Morales-Ruiz and Jos{\'e} Vilar and Patrick Maxwell and Vinores, {Stanley A.} and Geert Carmeliet and Mieke Dewerchin and Lena Claesson-Welsh and Evelyne Dupuy and {Van Vlierberghe}, Hans and Gerhard Christofori and Massimiliano Mazzone and Michael Detmar and D{\'e}sir{\'e} Collen",

year = "2010",

month = jan,

day = "1",

doi = "10.1016/j.cell.2010.02.039",

language = "English",

volume = "141",

pages = "178--190",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "1",

}

Van de Veire, S, Stalmans, I, Heindryckx, F, Oura, H, Tijeras-Raballand, A, Schmidt, T, Loges, S, Albrecht, I, Jonckx, B, Vinckier, S, Van Steenkiste, C, Tugues, S, Rolny, C, De Mol, M, Dettori, D, Hainaud, P, Coenegrachts, L, Contreres, JO, Van Bergen, T, Cuervo, H, Xiao, WH, Le Henaff, C, Buysschaert, I, Masouleh, BK, Geerts, A, Schomber, T, Bonnin, P, Lambert, V, Haustraete, J, Zacchigna, S, Rakic, JM, Jiménez, W, Noël, A, Giacca, M, Colle, I, Foidart, JM, Tobelem, G, Morales-Ruiz, M, Vilar, J, Maxwell, P, Vinores, SA, Carmeliet, G, Dewerchin, M, Claesson-Welsh, L, Dupuy, E, Van Vlierberghe, H, Christofori, G, Mazzone, M, Detmar, M & Collen, D 2010, 'Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease', Cell, vol. 141, no. 1, pp. 178-190. https://doi.org/10.1016/j.cell.2010.02.039

TY - JOUR

T1 - Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

AU - Van de Veire, Sara

AU - Stalmans, Ingeborg

AU - Heindryckx, Femke

AU - Oura, Hajimu

AU - Tijeras-Raballand, Annemilaï

AU - Schmidt, Thomas

AU - Loges, Sonja

AU - Albrecht, Imke

AU - Jonckx, Bart

AU - Vinckier, Stefan

AU - Van Steenkiste, Christophe

AU - Tugues, Sònia

AU - Rolny, Charlotte

AU - De Mol, Maria

AU - Dettori, Daniela

AU - Hainaud, Patricia

AU - Coenegrachts, Lieve

AU - Contreres, Jean Olivier

AU - Van Bergen, Tine

AU - Cuervo, Henar

AU - Xiao, Wei Hong

AU - Le Henaff, Carole

AU - Buysschaert, Ian

AU - Masouleh, Behzad Kharabi

AU - Geerts, Anja

AU - Schomber, Tibor

AU - Bonnin, Philippe

AU - Lambert, Vincent

AU - Haustraete, Jurgen

AU - Zacchigna, Serena

AU - Rakic, Jean Marie

AU - Jiménez, Wladimiro

AU - Noël, Agnes

AU - Giacca, Mauro

AU - Colle, Isabelle

AU - Foidart, Jean Michel

AU - Tobelem, Gerard

AU - Morales-Ruiz, Manuel

AU - Vilar, José

AU - Maxwell, Patrick

AU - Vinores, Stanley A.

AU - Carmeliet, Geert

AU - Dewerchin, Mieke

AU - Claesson-Welsh, Lena

AU - Dupuy, Evelyne

AU - Van Vlierberghe, Hans

AU - Christofori, Gerhard

AU - Mazzone, Massimiliano

AU - Detmar, Michael

AU - Collen, Désiré

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

AB - Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

KW - Cellcylce

KW - Cellimunno

KW - Humdisease

UR - http://www.scopus.com/inward/record.url?scp=77950960449&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2010.02.039

DO - 10.1016/j.cell.2010.02.039

M3 - Article

AN - SCOPUS:77950960449

SN - 0092-8674

VL - 141

SP - 178

EP - 190

JO - Cell

JF - Cell

IS - 1

ER -

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this